Abstract
Purpose: To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer. Methods: Between January 2008 and October 2012, patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment were retrospectively investigated. Clinical PET type was defined as follows: pancreatic cancer with similar 18 FDG uptake to renal calyx was determined as kidney-type (K-type), and relatively lower 18 FDG uptake than that of renal calyx was regarded as Non-K type. Results: A total of 53 patients were enrolled. After agreement-based reclassification, agreement based K-type (aK-type) was noted in 34 patients (64.2%), and agreement based Non-K type (aNon K-type) was found in 19 patients (35.8%). There was a significant difference between aK-type and aNon K-type pancreatic cancer (tumor size (P = 0.030), adjusted CA 19-9 (P = 0.007), maximum standard uptake value (SUV max ,P<0.001), metabolic tumor volume (MTV 2.5 , P<0.001), total lesion glycolysis (TLG, P<0.001)). K-type pancreatic cancer (n = 31) showed a significantly shorter disease-free time compared with Non-K type (n = 16) (10.8 vs. 24.1 months, P = 0.013). It was also noted that aK-type showed inferior diseasefree survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, P = 0.012). Conclusions; Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.
| Original language | English |
|---|---|
| Article number | e0172606 |
| Journal | PloS one |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2017 Feb |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biochemistry, Genetics and Molecular Biology(all)
- Agricultural and Biological Sciences(all)
Cite this
}
Clinically determined type of 18 F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer . / Chong, Jae Uk; Hwang, Ho Kyoung; Lee, Jin Ho; Yun, Mijin; Kang, Chang Moo; Lee, Woo Jung.
In: PloS one, Vol. 12, No. 2, e0172606, 02.2017.Research output: Contribution to journal › Article
TY - JOUR
T1 - Clinically determined type of 18 F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer
AU - Chong, Jae Uk
AU - Hwang, Ho Kyoung
AU - Lee, Jin Ho
AU - Yun, Mijin
AU - Kang, Chang Moo
AU - Lee, Woo Jung
PY - 2017/2
Y1 - 2017/2
N2 - Purpose: To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer. Methods: Between January 2008 and October 2012, patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment were retrospectively investigated. Clinical PET type was defined as follows: pancreatic cancer with similar 18 FDG uptake to renal calyx was determined as kidney-type (K-type), and relatively lower 18 FDG uptake than that of renal calyx was regarded as Non-K type. Results: A total of 53 patients were enrolled. After agreement-based reclassification, agreement based K-type (aK-type) was noted in 34 patients (64.2%), and agreement based Non-K type (aNon K-type) was found in 19 patients (35.8%). There was a significant difference between aK-type and aNon K-type pancreatic cancer (tumor size (P = 0.030), adjusted CA 19-9 (P = 0.007), maximum standard uptake value (SUV max ,P<0.001), metabolic tumor volume (MTV 2.5 , P<0.001), total lesion glycolysis (TLG, P<0.001)). K-type pancreatic cancer (n = 31) showed a significantly shorter disease-free time compared with Non-K type (n = 16) (10.8 vs. 24.1 months, P = 0.013). It was also noted that aK-type showed inferior diseasefree survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, P = 0.012). Conclusions; Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.
AB - Purpose: To investigate the association between clinical PET (positron emission tomography) type and oncologic outcome in resectable pancreatic cancer. Methods: Between January 2008 and October 2012, patients who underwent potentially curative resection for resectable pancreatic ductal adenocarcinoma without neoadjuvant treatment were retrospectively investigated. Clinical PET type was defined as follows: pancreatic cancer with similar 18 FDG uptake to renal calyx was determined as kidney-type (K-type), and relatively lower 18 FDG uptake than that of renal calyx was regarded as Non-K type. Results: A total of 53 patients were enrolled. After agreement-based reclassification, agreement based K-type (aK-type) was noted in 34 patients (64.2%), and agreement based Non-K type (aNon K-type) was found in 19 patients (35.8%). There was a significant difference between aK-type and aNon K-type pancreatic cancer (tumor size (P = 0.030), adjusted CA 19-9 (P = 0.007), maximum standard uptake value (SUV max ,P<0.001), metabolic tumor volume (MTV 2.5 , P<0.001), total lesion glycolysis (TLG, P<0.001)). K-type pancreatic cancer (n = 31) showed a significantly shorter disease-free time compared with Non-K type (n = 16) (10.8 vs. 24.1 months, P = 0.013). It was also noted that aK-type showed inferior diseasefree survival to that of aNon-K type pancreatic cancer (11.9 vs. 28.6 months, P = 0.012). Conclusions; Clinical PET type is a reliable clinical marker to estimate aggressive tumor biology and can be utilized in predicting tumor recurrence and necessity for postoperative chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85013874355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013874355&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0172606
DO - 10.1371/journal.pone.0172606
M3 - Article
C2 - 28235029
AN - SCOPUS:85013874355
VL - 12
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 2
M1 - e0172606
ER -